-
1Academic Journal
Authors: Karaban, I.M., Karasevych, N.V.
Source: INTERNATIONAL NEUROLOGICAL JOURNAL; № 5.91 (2017); 52-58
МЕЖДУНАРОДНЫЙ НЕВРОЛОГИЧЕСКИЙ ЖУРНАЛ; № 5.91 (2017); 52-58
МІЖНАРОДНИЙ НЕВРОЛОГІЧНИЙ ЖУРНАЛ; № 5.91 (2017); 52-58Subject Terms: 03 medical and health sciences, 0302 clinical medicine, Parkinson's disease, dopamine, dopamine receptor agonists, хвороба Паркінсона, дофамін, агоністи дофамінових рецепторів, болезнь Паркинсона, дофамин, агонисты дофаминовых рецепторов, 3. Good health
File Description: application/pdf
Access URL: http://inj.zaslavsky.com.ua/article/view/110857
-
2Academic Journal
Subject Terms: пролактинома, агонисты дофаминовых рецепторов, лучевая терапия, prolactinoma, resistance to therapy, transnasal transsphenoidal adenomectomy, stereotactic radiotherapy, резистентность к терапии, трансназальная трансфеноидальная аденомэктомия, 3. Good health, dopamine receptor agonists, стереотаксическая радиотерапия
-
3Academic Journal
Authors: E. A. Katunina, Z. A. Zalyalova, D. V. Pokhabov, M. Z. Ivanova, A. M. Semenova, Е. А. Катунина, З. А. Залялова, Д. В. Похабов, М. З. Иванова, А. М. Семенова
Contributors: This article has been supported by Servier, Статья спонсируется компанией «Сервье»
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 15, No 3 (2023); 95-103 ; Неврология, нейропсихиатрия, психосоматика; Vol 15, No 3 (2023); 95-103 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-3
Subject Terms: пирибедил, initial stages, dopamine receptor agonists, piribedil, начальные стадии, агонисты дофаминовых рецепторов
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/2036/1542; Tysnes O-B, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017 Aug;124(8):901-5. doi:10.1007/s00702-017-1686-y. Epub 2017 Feb 1.; Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003 MarApr;24(2):197-211. doi:10.1016/s01974580(02)00065-9; Pinter B, Diem-Zangerl A, Wenning GK, et al. Mortality in Parkinson’s disease: a 38-year follow-up study. Mov Disord. 2015 Feb;30(2):266-9. doi:10.1002/mds.26060. Epub 2014 Dec 1. Erratum in: Mov Disord. 2017 Jan;32(1):178.; Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007 Jan 30;68(5):384-6. doi:10.1212/01.wnl.0000247740.47667.03. Epub 2006 Nov 2.; Lunati A, Lesage S, Brice A. The genetic landscape of Parkinson’s disease. Rev Neurol (Paris). 2018 Nov;174(9):628-43. doi:10.1016/j.neurol.2018.08.004. Epub 2018 Sep 21.; Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol. 2007 Dec;33(6):599-614. doi:10.1111/j.13652990.2007.00874.x. Epub 2007 Oct 24.; Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna). 2003 May;110(5):517-36. doi:10.1007/s00702-002-0808-2; Borghammer P. How does Parkinson’s disease begin? Perspectives on neuroanatomical pathways, prions, and histology. Mov Disord. 2018 Jan;33(1):4857. doi:10.1002/mds.27138. Epub 2017 Aug 26.; Holmqvist S, Chutna O, Bousset L, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 2014 Dec;128(6):80520. doi:10.1007/s00401-014-1343-6. Epub 2014 Oct 9.; Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol. 2016 Jun;79(6):940-9. doi:10.1002/ana.24648. Epub 2016 Apr 9.; Pan-Montojo F, Anichtchik O, Dening Y, et al. Progression of Parkinson’s disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One. 2010 Jan 19;5(1):e8762. doi:10.1371/journal.pone.0008762; Svensson E, Horvath-Puho E, Thomsen RW, et al. Vagotomy and subsequent risk of Parkinson’s disease. Ann Neurol. 2015 Oct;78(4):522-9. doi:10.1002/ana.24448. Epub 2015 Jul 17.; Liu B, Fang F, Pedersen NL, et al. Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study. Neurology. 2017 May 23;88(21):1996-2002. doi:10.1212/WNL.0000000000003961. Epub 2017 Apr 26.; Lionnet A, Leclair-Visonneau L, Neunlist M, et al. Does Parkinson’s disease start in the gut? Acta Neuropathol. 2018 Jan;135(1):1-12. doi:10.1007/s00401-0171777-8. Epub 2017 Oct 16.; Gjerloff T, Fedorova T, Knudsen K, et al. Imaging acetylcholinesterase density in peripheral organs in Parkinson’s disease with 11C-donepezil PET. Brain. 2015 Mar;138(Pt 3):653-63. doi:10.1093/brain/awu369. Epub 2014 Dec 23.; Knudsen K, Fedorova TD, Hansen AK, et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol. 2018 Jul;17(7):618-28. doi:10.1016/S14744422(18)30162-5. Epub 2018 Jun 1.; Iranzo A, Fernandez-Arcos A, Tolosa E, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One. 2014 Feb 26;9(2):e89741. doi:10.1371/journal.pone.0089741; Miyamoto T, Miyamoto M, Inoue Y, et al. Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Neurology. 2006 Dec 26;67(12):2236-8. doi:10.1212/01.wnl.0000249313.25627.2e; Kashihara K, Imamura T, Shinya T. Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson’s disease. Parkinsonism Relat Disord. 2010 May;16(4):252-5. doi:10.1016/j.parkreldis.2009.12.010. Epub 2010 Jan 25.; Orimo S, Yogo M, Nakamura T, et al. (123)I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α-synucleinopathies. Ageing Res Rev. 2016 Sep;30:122-33. doi:10.1016/j.arr.2016.01.001. Epub 2016 Feb 2.; Knudsen K, Fedorova TD, Horsager J, et al. Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson’s Disease Subtypes. J Parkinsons Dis. 2021;11(4):1677-87. doi:10.3233/JPD-212761; Horsager J, Andersen KB, Knudsen K, et al. Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study. Brain. 2020 Oct 1;143(10):3077-88. doi:10.1093/brain/awaa238; Borghammer P. The α-synuclein origin and Connectome Model (SOC model) of Parkinson’s disease: Explaining motor asymmetry, non-motor phenotypes, and cognitive decline. J Parkinson’s Dis. 2021;11(2):455-74. doi:10.3233/JPD-202481; Berg D, Postuma RB, Adler CH, et al. MDS research criteria for Prodromal Parkinson’s disease. Mov Disord. 2015 Oct;30(12):1600-11. doi:10.1002/mds.26431; Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015 Oct;30(12):1591-601. doi:10.1002/mds.26424; Иллариошкин СН, Левин ОС, редакторы. Руководство по диагностике и лечению болезни Паркинсона. Москва: ООО «ИПК Парето-Принт»; 2017. 336 с.; Селихова МВ, Катунина ЕА, Воун А. Позитронная эмиссионная и однофотонная эмиссионная компьютерная томография в оценке состояния моноаминергических систем мозга при экстрапирамидных расстройствах. Анналы клинической и экспериментальной неврологии. 2019;13(2):69-78. doi:10.25692/ACEN.2019.2.8; Болезнь Паркинсона, вторичный паркинсонизм и другие заболевания, проявляющиеся синдромом паркинсонизма. Клинические рекомендации. 2021. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/716_1 Bolezn’ Parkinsona, vtorichnyi parkinsonism i drugie zabolevaniya, proyavlyayushchiesya sindromom parkinsonizma; Нарушения обмена меди (болезнь Вильсона). Клинические рекомендации. 2021. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/376_2; Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-es recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol. 2013 Jan;20(1):16-34. doi:10.1111/ene.12022. Erratum in: Eur J Neurol. 2013 Feb;20(2):406.; D Med Collaborative Group; Gray R, Ives N, Rick C, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014 Sep 27;384(9949):1196-205. doi:10.1016/S0140-6736(14)60683-8. Epub 2014 Jun 11. Erratum in: Lancet. 2014 Sep 27;384(9949):1186.; Bergamasco B, Frattola L, Muratorio A, et al. Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study. Acta Neurol Scand. 2000 Jun;101(6):372-80. doi:10.1034/j.16000404.2000.90295a.x; Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group. Neurology. 1997 Sep;49(3):724-8. doi:10.1212/wnl.49.3.724. Erratum in: Neurology. 1998 Mar;50(3):838.; Finotti N, Castagna L, Moretti A, Marzatico F. Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment. Pharmacol Res. 2000;42(4):287-91. doi:10.1006/phrs.2000.0690; Le W-D, Jankovic J. Are dopamine receptors agonists neuroprootective in Parkinson’s disease? Drugs Aging. 2001;18(6):389-96. doi:10.2165/00002512-200118060-00001; Nishibayashi S, Asanuma M, Kohno M, et al. Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem. 1996;67(5):2208-11. doi:10.1046/j.14714159.1996.67052208.x; Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. New Engl J Med. 2000;342(20):1484-91. doi:10.1056/nejm200005183422004; Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002 Apr 3;287(13):1653-61. doi:10.1001/jama.287.13.1653; Whone AL, Watts RL, Stoessl AJ, et al; REAL-PET Study Group. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003 Jul;54(1):93-101. doi:10.1002/ana.10609; Schapira A, Albrecht S, Barone P, et al. P1.203 immediate vs. delayed-start pramipexole in early Parkinson’s disease: The proud study. Parkinsonism Relat Disord. 2009;15:S81. doi:10.1016/s1353-8020(09)70325-6; Gerlach M, Double K, Arzberger T, et al. Dopamine receptor agonists in current clinical use: Comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transmis. 2003;110(10):1119-27. doi:10.1007/s00702-003-0027-5; Etminan M, Samii A, Takkouche B, Rochon PA. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson’s disease. Drug Saf. 2001;24(11):863-8. doi:10.2165/00002018200124110-00007; Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson’s disease. Drug Saf. 2009;32(6):475-88. doi:10.2165/00002018-200932060-00004; Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson’s disease. Arch Neurol. 2010 May;67(5):589-95. doi:10.1001/archneurol.2010.65; Isaias IU, Siri C, Cilia R, et al. The relationship between impulsivity and impulse control disorders in Parkinson’s disease. Mov Disord. 2008;23(3):411-5. doi:10.1002/mds.21872; Weintraub D, Hoops S, Shea JA, et al. Validation of the questionnaire for impulsivecompulsive disorders in Parkinson’s disease. Mov Disord. 2009;24(10):1461-7. doi:10.1002/mds.22571; Weintraub D, Rektorova I. Impulse control disorders and related behaviors. In: D Aarsland, J Cummings, D Weintraub, K Chaudhuri, editors. Neuropsychiatric and Cognitive Changes in Parkinson’s Disease and Related Movement Disorders: Diagnosis and Management. Cambridge: Cambridge University Press; 2013. P. 140-52. doi:10.1017/CBO9781139856669.014; Joutsa J, Martikainen K, Vahlberg T, et al. Impulse control disorders and depression in Finnish patients with Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(2):155-60. doi:10.1016/j.parkreldis.2011.09.007; Antonini A, Barone P, Bonuccelli U, et al. Icarus study: Prevalence and clinical features of impulse control disorders in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2017;88(4):317-24. doi:10.1136/jnnp-2016315277; Thorlund K, Wu P, Druyts E, et al. Nonergot dopamine-receptor agonists for treating Parkinson’s disease – a network meta-analysis. Neuropsychiatr Dis Treatm. 2014;2014:767-76. doi:10.2147/ndt.s60061; LeWitt PA, Boroojerdi B, MacMahon D, et al. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson’s disease. Clin Neuropharmacol. 2007;30(5):256-65. doi:10.1097/wnf.0b013e318154c7c4; Millan MJ. From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson’s disease. Pharmacol Ther. 2010;128(2):229-73. doi:10.1016/j.pharmthera.2010.06.002; Gobert A, Di Cara B, Cistarelli L, Millan MJ. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of α2aadrenoceptors: A dialysis comparison to Talipexole and Quinelorane in the absence of acetylcholinesterase inhibitors. J Pharmacol Exper Ther. 2003;305(1):338-46. doi:10.1124/jpet.102.046383; Delaville C, Deurwaerdere PD, Benazzouz A. Noradrenaline and Parkinson’s disease. Front Syst Neurosci. 2011 May 18;5:31. doi:10.3389/fnsys.2011.00031. eCollection 2011.; Djaldetti R, Mosberg-Galili R, Sroka H, et al. Camptocormia (Bent Spine) in patients with Parkinson’s disease characterization and possible pathogenesis of an unusual phenomenon. Mov Disord. 1999;14(3):443-7. doi:10.1002/1531-8257(199905)14:33.0.co;2-g; Suzuki M, Hirai T, Ito Y, et al. Pramipexole-induced antecollis in Parkinson’s disease. J Neurol Sci. 2008;264(1-2):195-7. doi:10.1016/j.jns.2007.08.008; Calzi F, Bellasio R, Guiso G, et al. Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo. Eur J Pharmacol. 1997;338(2):185-90. doi:10.1016/s0014-2999(97)81947-4; Munchau A. Pharmacological treatment of Parkinson’s disease. Postgrad Med J. 2000;76(900):602-10. doi:10.1136/pmj.76.900.602; Rascol O, Dubois B, Caldas AC, et al. Early Piribedil monotherapy of Parkinson’s disease: A planned seven-month report of the Regain Study. Mov Disord. 2006;21(12):2110-5. doi:10.1002/mds.21122; Rondot P, Ziegler M. Activity and acceptability of Piribedil in Parkinson’s disease: A multicentre study. J Neurol. 1992;239 Suppl 1:S28-34. doi:10.1007/BF00819564; Chen X, Ren C, Li J, et al. The efficacy and safety of Piribedil relative to pramipexole for the treatment of early Parkinson’s disease: A systematic literature review and network meta-analysis. Clin Neuropharmacol. 2020;43(4):100-6. doi:10.1097/wnf.0000000000000400; Aarsland D, Bronnick K, Larsen JP, et al. Cognitive impairment in incident, untreated Parkinson’s disease: The Norwegian Parkwest Study. Neurology. 2009;72(13):1121-6. doi:10.1212/01.wnl.0000338632.00552.cb; Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson’s disease: A Multicenter pooled analysis. Neurology. 2010;75(12):1062-9. doi:10.1212/wnl.0b013e3181f39d0e; Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: Critical review of pd-MCI. Mov Disord. 2011;26(10):1814-24. doi:10.1002/mds.23823; Yarnall AJ, Breen DP, Duncan GW, et al. Characterizing mild cognitive impairment in incident Parkinson’s disease: The Icicle-PD Study. Neurology. 2014;82(4):308-16. doi:10.1212/wnl.0000000000000066; Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson’s disease. J Neurol Sci. 2010;289(1-2):18-22. doi:10.1016/j.jns.2009.08.034; Buter TC, van den Hout A, Matthews FE, et al. Dementia and survival in Parkinson’s disease: A 12-year population study. Neurology. 2008;70(13):1017-22. doi:10.1212/01.wnl.0000306632.43729.24; Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson’s disease: Diagnosis, biomarkers, and treatment. Lancet Neurol. 2012;11(8):697707. doi:10.1016/s1474-4422(12)70152-7; Федорова НВ, Артемьева ЕГ, Чигирь ИП, Левин ОС. Применение пронорана (пирибедила) при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2003;103(9):71-2.; Пилипович АА, Голубев ВЛ. Влияние Пронорана на когнитивные и аффективные нарушения при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2005;105(4):41-7.; Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: Value of a dopaminergic agonist, Piribedil. J Neurol. 1992;239(S1):13-6. doi:10.1007/bf00819561; Valdes P, Schneider BL. Gene therapy: A promising approach for neuroprotection in Parkinson’s disease? Front Neuroanat. 2016 Dec 20;10:123. doi:10.3389/fnana.2016.00123.eCollection2016.; Brocco M, Dekeyne A, Papp M, Millan MJ. Antidepressant-like properties of the anti-parkinson agent, Piribedil, in rodents: Mediation by dopamine D2 receptors. Behav Pharmacol. 2006;17(7):559-72. doi:10.1097/01.fbp.0000236267.41806.5b; Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex – basal ganglia circuits. Cerebral Cortex. 2006;16(7):916-28. doi:10.1093/cercor/bhj043; Dujardin K, Defebvre L. Apathy in Parkinson’s disease: What are the underlying mechanisms? Neurology. 2012;79(11):1082-3. doi:10.1212/wnl.0b013e3182698dd4; Starkstein SE. Apathy in Parkinson’s disease: Diagnostic and Etiological Dilemmas. Mov Disord. 2012;27(2):174-8. doi:10.1002/mds.24061; Pluck GC. Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):636-42. doi:10.1136/jnnp.73.6.636; Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord. 2009;24(15):2175-86. doi:10.1002/mds.22589; Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573-80. doi:10.1016/s1474-4422(10)70106-x; Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in Advanced Parkinson’s Disease. N Engl J Med. 2003;349(20):1925-34. doi:10.1056/nejmoa035275; Funkiewiez A. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75(6):834-9. doi:10.1136/jnnp.2002.009803; Czernecki V, Schüpbach M, Yaici S, et al. Apathy following subthalamic stimulation in Parkinson’s disease: A dopamine responsive symptom. Mov Disord. 2008;23(7):964-9. doi:10.1002/mds.21949; Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: A randomised, Multicentre Study. Lancet Neurol. 2008;7(7):605-14. doi:10.1016/s1474-4422(08)70114-5; Remy P, Doder M, Lees A, et al. Depression in Parkinson’s disease: Loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128(6):131422. doi:10.1093/brain/awh445; Thobois S, Ardouin C, Lhommee E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: Predictors and underlying mesolimbic denervation. Brain. 2010;133(4):1111-27. doi:10.1093/brain/awq032; Schrag A. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):30812. doi:10.1136/jnnp.69.3.308; Voon V, Fernagut P-O, Wickens J, et al. Chronic dopaminergic stimulation in Parkinson’s disease: From Dyskinesias to impulse control disorders. Lancet Neurol. 2009;8(12):1140-9. doi:10.1016/s14744422(09)70287-x; Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson’s disease: Dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464-74. doi:10.1016/s1474-4422(09)70068-7; Thobois S, Lhommee E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with Piribedil. Brain. 2013;136(5):1568-77. doi:10.1093/brain/awt067; Paus S, Brecht HM, Köster J, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s disease. Mov Disord. 2003;18(6):659-67. doi:10.1002/mds.10417; Borek LL, Amick MM, Friedman JH. Non-motor aspects of Parkinson’s disease. CNSSpectrums. 2006;11(7):541-54. doi:10.1017/s1092852900013560; Tracik F, Ebersbach G. Sudden daytime sleep onset in Parkinson’s disease: Polysomnographic recordings. Mov Disord. 2001;16(3):500-6. doi:10.1002/mds.1083; Ulivelli M, Rossi S, Lombardi C, et al. Polysomnographic characterization of pergolide-induced sleep attacks in idiopathic PD. Neurology. 2002;58(3):462-5. doi:10.1212/wnl.58.3.462; Allcock LM, Rowan EN, Steen IN, et al. Impaired attention predicts falling in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(2):110-5. doi:10.1016/j.parkreldis.2008.03.010; Meindorfner C, Körner Y, Möller JC, et al. Driving in Parkinson’s disease: Mobility, accidents, and sudden onset of sleep at the wheel. Mov Disord. 2005;20(7):832-42. doi:10.1002/mds.20412; Drouot X, Moutereau S, Nguyen JP, et al. Low levels of ventricular CSF orexin/hypocretin in Advanced PD. Neurology. 2003;61(4):540-3. doi:10.1212/01.wnl.0000078194.53210.48; Poewe W, Hogl B. Sleep and Parkinson’s disease. Editional review. Curr Opin Neurol. 2000 Aug;13(4):423-6. doi:10.1097/00019052200008000-00009; Verbaan D, van Rooden SM, Visser M, et al. Nighttime sleep problems and daytime sleepiness in Parkinson’s disease. Mov Disord. 2008;23(1):35-41. doi:10.1002/mds.21727; Wood LD. Clinical Review and treatment of select adverse effects of dopamine receptor agonists in Parkinson’s disease. Drugs Aging. 2010;27(4):295-310. doi:10.2165/11318330000000000-00000; Monaca C, Duhamel A, Jacquesson JM, et al. Vigilance troubles in Parkinson’s disease: A subjective and objective polysomnographic study. Sleep Med. 2006;7(5):448-53. doi:10.1016/j.sleep.2005.12.002; Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: Motor Vehicle Mishaps in persons taking pramipexole and Ropinirole. Neurology. 1999 Jun 10;52(9):1908-10. doi:10.1212/wnl.52.9.1908; Eggert K, Еhlwein C, Kassubek J, et al. Influence of the nonergot dopamine agonist Piribedil on vigilance in patients with Parkinson’s disease and excessive daytime sleepiness (PiViCog-PD). Clin Neuropharmacol. 2014;37(4):116-22. doi:10.1097/wnf.0000000000000041; Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of Antiparkinson agents at multiple classes of monoaminergic receptor. i. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exper Ther. 2002;303(2):791-804. doi:10.1124/jpet.102.039867; Katunina EA, Blokhin V, Nodel MR, et al. Searching for biomarkers in the blood of patients at risk of developing Parkinson’s disease at the Prodromal Stage. Int J Mol Sci. 2023;24(3):1842. doi:10.3390/ijms24031842
-
4Academic Journal
Authors: A. A. Tappakhov, T. E. Popova, A. I. Vasilev, T. G. Govorova, Yu. I. Khabarova, K. A. Timofeeva, N. A. Schnaider, А. А. Таппахов, Т. Е. Попова, А. И. Васильев, Т. Г. Говорова, Ю. И. Хабарова, К. А. Тимофеева, Н. А. Шнайдер
Contributors: The study was supported by the Grant of the President of the Russian Federation for state support of young Russian scientists – PhDs and professors and leading scientific schools of the Russian Federation МК-2254.2020.7 «Pharmacogenetic approach to the prevention of complications of antiparkinsonian therapy»
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 13, No 3 (2021); 75-81 ; Неврология, нейропсихиатрия, психосоматика; Vol 13, No 3 (2021); 75-81 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2021-3
Subject Terms: систематический обзор, levodopa, dopamine receptor agonists, amantadine, MAO-B inhibitors, personalized medicine, adverse drug reactions, meta-analysis, systematic review, леводопа, агонисты дофаминовых рецепторов, амантадин, ингибиторы МАО-В, персонализированная медицина, нежелательные реакции, метаанализ
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/1580/1258; Левин ОС, Артемьев ДВ, Бриль ЕВ и др. Болезнь Паркинсона: современные подходы к диагностике и лечению. Практическая медицина. 2017;1(102):45-51.; Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson’s disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017 Sep;32(9):1264-310. doi:10.1002/mds.27115; Вереютина ИА, Журавлева ЕЮ, Иллариошкин СН и др. Новые возможности терапии нейропсихологических нарушений у пациентов на ранней стадии болезни Паркинсона. Кремлевская медицина. Клинический вестник. 2013;(3):20-4.; Нодель МР. Нарушения сна при болезни Паркинсона. Неврология, нейропсихиатрия, психосоматика. 2011;3(1):51-55. doi:10.14412/2074-2711-2011-135; Lewitt PA. Levodopa therapy for Parkinson’s disease: Pharmacokinetics and pharmacodynamics. Mov Disord. 2015 Jan;30(1):64-72. doi:10.1002/mds.26082. Epub 2014 Dec 1.; Титова НВ, Катунина ЕА. Леводопа: история продолжается. Журнал неврологии и психиатрии им. С.С. Корсакова. 2014;(9):93-9.; Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson’s Disease: Current Status and Future Developments. Curr Neuropharmacol. 2017;16(8):1239-52. doi:10.2174/1570159x15666170510143821; Müller T. Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2020;16(5):403-14. doi:10.1080/17425255.2020.1750596; Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease. CNS Drugs. 2010;24(11):941-68. doi:10.2165/11537810-000000000-00000; Парфенов ВА. Ранняя диагностика и лечение болезни Альцгеймера. Медицинский совет. 2015;(5):28-33.; Dezsi L, Vecsei L. Monoamine oxidase B inhibitors in Parkinson’s disease. CNS Neurol Disord Drug Targets. 2017;16(4):425-39. doi:10.2174/1871527316666170124165222; Sawada H, Oeda T, Kuno S, et al. Amantadine for dyskinesias in Parkinson’s disease: A randomized controlled trial. PLoS One. 2010;5(12):6-12. doi:10.1371/journal.pone.0015298; Иллариошкин СН. Производные амантадина в лечении болезни Паркинсона. Нервные болезни. 2016;(3):14-9.; Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013;20:5-15. doi:10.1111/j.1468-1331.2012.03866.x; DeMaagd G, Philip A. Parkinson’s Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options. P T. 2015 Oct;40(10):668-79.; Reichmann H, Boas J, MacMahon D, et al. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand. 2005;111(1):21-8. doi:10.1111/j.1600-0404.2004.00363.x; Brooks DJ, Agid Y, Eggert K, et al. Treatment of end-of-dose wearing-off in Parkinson’s disease: Stalevo® (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess®/Comtan® (entacapone) provide equivalent improvements in symptom control superior to that of traditio. Eur Neurol. 2005;53(4):197-202. doi:10.1159/000086479; Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson Disease: A 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044- 53. doi:10.1001/archneur.61.7.1044; Tolosa E, Stern MB. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson’s disease. Eur J Neurol. 2012;19(2):258-64. doi:10.1111/j.1468-1331.2011.03484.x; Viallet F, Pitel S, Lancrenon S, et al. Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson’s disease. Curr Med Res Opin. 2013;29(1):23-31. doi:10.1185/03007995.2012.752351; Wong KS, Lu CS, Shan DE, et al. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson’s disease. J Neurol Sci. 2003;216(1):81-7. doi:10.1016/S0022-510X(03)00217-X; Rascol O, Dubois B, Castro Caldas A, et al. Early piribedil monotherapy of parkinson’s disease: A planned seven-month report of the REGAIN study. Mov Disord. 2006;21(12):2110-5. doi:10.1002/mds.21122; Elmer LW, Juncos JL, Singer C, et al. Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease. CNS Drugs. 2018;32(4):387-98. doi:10.1007/s40263-018-0498-4; Parkinson Study Group. A Controlled Trial of Rasagiline in Early Parkinson Disease. The TEMPO Study. Arch Neurol. 2002 Dec;59(12):1937-43. doi:10.1001/archneur.59.12.1937; Lew MF, Pahwa R, Leehey M, et al. Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of «off» episodes in patients with Parkinson’s disease. Curr Med Res Opin. 2007;23(4):741-50. doi:10.1185/030079906X167697; Hattori N, Hasegawa K, Sato K, et al. Clinical evaluation of ropinirole controlledrelease formulation at 18–24 mg/day in Japanese patients with Parkinson's disease. Parkinsonism Relat Disord. 2017;40:33-9. doi:10.1016/j.parkreldis.2017.04.005; Koller W, Guarnieri M, Hubble J, et al. An open-label evaluation of the tolerability and safety of Stalevo® (carbidopa, levodopa and entacapone) in Parkinson’s disease patients experiencing wearing-off. J Neural Transm. 2005;112(2):221-30. doi:10.1007/s00702-004-0184-1; Eggert K, Skogar Ö, Amar K, et al. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: Efficacy, safety and feasibility-an open-label, 6-week study. J Neural Transm. 2010;117(3):333-42. doi:10.1007/s00702-009-0344-4; Kuoppamäki M, Leinonen M, Poewe W. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off. J Neural Transm. 2015;122(12):1709-14. doi:10.1007/s00702-015-1449-6; Brunt ER, Brooks DJ, Korczyn AD, et al. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson’s disease not optimally controlled by L-dopa. J Neural Transm. 2002;109(4):489-502. doi:10.1007/s007020200040; Zhang Z, Wang J, Zhang X, et al. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson’s disease: A multicenter, double-blind, randomized, placebo-controlled study. Park Relat Disord. 2013;19(11):1022-6. doi:10.1016/j.parkreldis.2013.07.009; Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: A randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry. 2002;72(6):713-20. doi:10.1136/jnnp.72.6.713; Verschuur CVM, Suwijn SR, Boel JA, et al. Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease. N Engl J Med. 2019;380(4):315-24. doi:10.1056/NEJMoa1809983; Катунина ЕА, Бездольный ЮН, Малыхина ЕА и др. Опыт применения леводопыбенсеразида. Неврология, нейропсихиатрия, психосоматика. 2015;7(3):93-7. doi:10.14412/2074-2711-2015-3-93-97; Сапронова МР, Шнайдер НА. Предикторы и модификаторы импульсивно-компульсивных расстройств при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;116(11):145-56. doi:10.17116/jnevro2016116111145-156; Biglan KM, Holloway RG, McDermott MP, et al. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology. 2007;69(2):187-95. doi:10.1212/01.wnl.0000265593.34438.00; Богданов РР, Богданов АР, Котов СВ. Тактика ведения пациентов с начальными проявлениями болезни Паркинсона. Доктор.ру. 2012;73(5):15-21.; Pahwa R, Tanner CM, Hauser RA, et al. ADS-5102 (Amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson Disease (EASE LID Study): A randomized clinical trial. JAMA Neurol. 2017;74(8):941-9. doi:10.1001/jamaneurol.2017.0943
-
5Academic Journal
Authors: Editorial Article
Source: Медицинский совет, Vol 0, Iss 18, Pp 30-35 (2015)
Subject Terms: болезнь паркинсона, нейродегенеративные заболевания, агонисты дофаминовых рецепторов, деменция, нервная система, parkinson's disease, Medicine
File Description: electronic resource
-
6
-
7Academic Journal
Authors: Bogdanov R.R., Borisova S.Y., Kotov S.V., Zavarzina O.O.
Source: Almanac of Clinical Medicine; Vol 44, No 3 (2016); 329-335 ; Альманах клинической медицины; Vol 44, No 3 (2016); 329-335 ; 2587-9294 ; 2072-0505 ; 10.18786/2072-0505-2016-44-3
Subject Terms: Parkinson's disease, non-motor symptoms, anxiety, neuropsychiatric problems, depression, dopamine agonists, pramipexol, болезнь Паркинсона, немоторные проявления, тревога, нейропсихиатрические нарушения, депрессия, агонисты дофаминовых рецепторов, прамипексол
File Description: application/pdf
Relation: https://almclinmed.ru/jour/article/view/355/360; https://almclinmed.ru/jour/article/view/355
-
8Academic Journal
Authors: КАРАБАНОВ А.В., ЕРШОВА М.В., ИЛЛАРИОШКИН С.Н.
Subject Terms: БОЛЕЗНЬ ПАРКИНСОНА,ПРОДОЛЖИТЕЛЬНАЯ ДОФАМИНЕРГИЧЕСКАЯ СТИМУЛЯЦИЯ,АГОНИСТЫ ДОФАМИНОВЫХ РЕЦЕПТОРОВ,МИРАПЕКС ПД
File Description: text/html
-
9Academic Journal
Authors: К. КУНАНБАЙ, Ж.Т. АБИЛХАНОВА
Subject Terms: паркинсонизм, холинолитические препараты, производные аминоадамантана, ДОФА-содержащие средства, ингибиторы моноаминоксидазы типа Б, ингибиторы катехол-О-метилтрансферазы и агонисты дофаминовых рецепторов
File Description: text/html
-
10Review
Subject Terms: пролактинома, агонисты дофаминовых рецепторов, лучевая терапия, prolactinoma, resistance to therapy, transnasal transsphenoidal adenomectomy, stereotactic radiotherapy, резистентность к терапии, трансназальная трансфеноидальная аденомэктомия, dopamine receptor agonists, стереотаксическая радиотерапия
-
11Academic Journal
Authors: Bogdanov R.R., Borisova S.Y., Kotov S.V.
Source: Almanac of Clinical Medicine; No 39 (2015); 90-96 ; Альманах клинической медицины; No 39 (2015); 90-96 ; 2587-9294 ; 2072-0505 ; 10.18786/2072-0505-2015-39
Subject Terms: Parkinsons disease, non-motor signs, anxiety, depression, cognitive dysfunction, dopamine agonists, pramipexole, болезнь Паркинсона, немоторные проявления, тревога, депрессия, когнитивные нарушения, агонисты дофаминовых рецепторов, прамипекcол
File Description: application/pdf
Relation: https://almclinmed.ru/jour/article/view/228/226; https://almclinmed.ru/jour/article/view/228
-
12Academic Journal
Subject Terms: БОЛЕЗНЬ ПАРКИНСОНА, НЕМОТОРНЫЕ ПРОЯВЛЕНИЯ, ТРЕВОГА, ДЕПРЕССИЯ, КОГНИТИВНЫЕ НАРУШЕНИЯ, АГОНИСТЫ ДОФАМИНОВЫХ РЕЦЕПТОРОВ, ПРАМИПЕКГАЛ, PARKINSON''S DISEASE
File Description: text/html
-
13Academic Journal
Authors: ФЕДОРОВА Н.В., НИКИТИНА А.В.
File Description: text/html
-
14Academic Journal
Authors: A. V. Obukhova, А. В. Обухова
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 6, No 3 (2014); 80-84 ; Неврология, нейропсихиатрия, психосоматика; Vol 6, No 3 (2014); 80-84 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2014-3
Subject Terms: агонисты дофаминовых рецепторов, dopamine receptor agonists
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/442/431; Артемьев ДВ. Эволюция дофаминергической терапии болезни Паркинсона. В кн.: Болезнь Паркинсона и расстройства движений. Руководство для врачей. Под ред. С.Н. Иллариошкина, Н.Н. Яхно. Москва: НЦН РАМН; 2008. С. 147–50. [Artem'ev DV. Evolution of dofaminergic therapy of an illness of Parkinson. In: Bolezn' Parkinsona i rasstroistva dvizhenii. Rukovodstvo dlya vrachei [Parkinson's; illness and disorders of the movements. The guide for doctors]. Illarioshkin SN, Yakhno NN, etidors. Moscow: NTsN RAMN; 2008. P. 147–50.]; Claveria LE, Calne DB, Allen JG. «On-off» phenomena related to high plasma levodopa. Br Med J. 1973;2(5867):641–3. DOI: http://dx.doi.org/10.1136/bmj.2.5867.641.; Tolosa ES, Martin WE, Cohen HP, Jacobson RL. Patterns of clinical response and plasma dopa levels in Parkinson's disease. Neurology. 1975 Feb;25(2):177–83. DOI: http://dx.doi.org/10.1212/WNL.25.2.177.; Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology. 1984 Sep;34(9):1131–6. DOI: http://dx.doi.org/10.1212/WNL.34.9.1131.; Федорова НВ, Кулуа ТК. Опыт применения прамипексола в лечении болезни Паркинсона. Consilium Medicum. 2007;9(2):103–7. [Fedorova NV, Kulua TK. Experience of application of a pramipeksol in treatment of an illness of Parkinson. Consilium Medicum. 2007;9(2):103–7. (In Russ.)]; Яхно НН, Нодель МР, Федорова НВ и др. Эффективность и переносимость прамипексола (Мирапекса) при продолжительной терапии у пациентов с болезнью Паркинсона. Неврологический журнал. 2004;9(3):25–30. [Yakhno NN, Nodel' MR, Fedorova NV, et al. Efficacy and tolerance of pramipexol (mirapex) in long-term therapy of patients with Parkinson's disease. Nevrologicheskii zhurnal. 2004;9(3):25–30. (In Russ.)]; Иллариошкин СН, Иванова-Смоленская ИА, Загоровская ТБ и др. Семилетний опыт применения Мирапекса у больных с различными формами первичного паркинсонизма. Журнал неврологии и психиатрии им. С.С. Корсакова. 2006;106(11):1–8. [Illarioshkin SN, Ivanova-Smolenskaya IA, Zagorovskaya TB, et al. Seven years’ experience of application of Mirapeks for patients with various forms of primary parkinsonism. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2006;106(11):1–8. (In Russ.)]; Reichmann H, Brecht MH, Kö ster J, at al. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson’s disease. CNS Drugs. 2003;17(13):965–73. DOI: http://dx.doi.org/10.2165/00023210-200317130-00003.; Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring, agonist useful in treating Parkinson’s disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141–51.; Hauser RA, McDermott MP, Messing S, et al. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 2006;63:1756–60. DOI: http://dx.doi.org/10.1001/archneur.63.12.1756.; Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease. A randomized controlled trial. JAMA. 2000;284:1931–8. DOI: http://dx.doi.org/10.1001/jama.284.15.1931.; Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61:1044–53.; Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162–8. DOI: http://dx.doi.org/10.1212/WNL.49.1.162.; Moller JC, Oertel WH, Koster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trial. Mov Disord. 2005;20(5):602–10. DOI: http://dx.doi.org/10.1002/mds.20397.; Weiner WJ, Factor SA, Jankovic J, et al. The long-term safety and efficacy of pramipexole in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2001;7(2):115–20. DOI: http://dx.doi.org/10.1016/S1353-8020(00)00031-6.; Иллариошкин СН. Возможности агониста дофаминовых рецепторов прамипексола в лечении болезни Паркинсона. Неврология, нейропсихиатрия, психосоматика. 2012;(2):78–83. [Illarioshkin SN. Capacities of the dopamine receptor agonist pramipexole in the treatment of patients with Parkinson’s disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;(2):78–83. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711- 2012-389.; Левин ОС, Бойко АН, Нестерова ОС и др. Влияние агониста дофаминовых рецепторов прамипексола (мирапекса) на тремор, аффективные нарушения и качество жизни у больных с болезнью Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2010;110(2):39–44. [Levin OS, Boiko AN, Nesterova OS, et al. Effect of dopamine agonist pramipexole (mirapex) on tremor, ffective disorders and quality of life in patients with Parkinson’s disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2010;110(2):39–44. (In Russ.)]; Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry. 2002;72:713–20. DOI: http://dx.doi.org/10.1136/jnnp.72.6.713.; Артемьев ДВ. Лечение болезни Паркинсона в молодом возрасте. Неврология, нейропсихиатрия, психосоматика. 2010;(3):6–11. [Artem’ev DV. Treatment of Parkinson's disease at a young age. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2010;(3):6–11. (In Russ.)]. DOI: http://dx.doi.org/10.14412/ 2074-2711-2010-93.; Нодель МР. Депрессия при болезни Паркинсона. Неврология, нейропсихиатрия, психосоматика. 2010;(4):11–7. [Nodel’ MR. Depression in Parkinson’s disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2010;(4):11–7. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2010-110.; Нодель МР, Яхно НН. Мирапекс (прамипексол) в лечении недвигательных нарушений при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2008;108(5):32–8. [Nodel’ MR, Yakhno NN. Mirapex (pramipexole) in the treatment of nonmotor disturbances in Parkinson’s disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2008;108(5):32–8. (In Russ.)]; Barone P, Scarzella L, Antonini A, et al. Pramipexole versus sertraline in the treatment of depression in Parkinsons disease. J Neurol. 2005;4:1–7.; Lemke MP, Brecht HM, Koester JK, et al. Anhedonia, depression, and motor functioning in Parkinsons disease during treatment with Pramipexole. J Neuropsych Clin Neurosci. 2005;17(2):214–20. DOI: http://dx.doi.org/10.1176/appi.neuropsych. 17.2.214.; Левин ОС, Тумгоева АИ. Применение новой лекарственной формы агониста дофаминовых рецепторов прамипексола в лечении болезни Паркинсона. Справочник поликлинического врача. 2011;(8):53–7. [Levin OS, Tumgoeva AI. Application of a new dosage form of an agonist of dopamine receptors of a pramipeksol in treatment of an illness of Parkinson. Spravochnik poliklinicheskogo vracha. 2011;(8):53–7. (In Russ.)]; Antonini A, Calandrella D. Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients. Neuropsychiatr Dis Treat. 2011;7:297–302. DOI: http://dx.doi.org/10.2147/NDT.S10097.; Eisenreich W, Sommer B, Hartter S, Jost WH. Pramipexole extended release: a novel treatment option in Parkinson’s disease. Parkinsons Dis. 2010;2010:612–9. DOI:10.4061/2010/612619.; Обухова АВ. Опыт применения прамипексола пролонгированного действия при болезни Паркинсона. Эффективная фармакотерапия. 2013;23:4–11. [Obukhova AV. Experience of using long-acting pramipexole in patients with Parkinson`s disease. Effektivnaya farmakoterapiya. 2013;23:4–11. (In Russ.)]; Обухова АВ, Артемьев ДВ. Новая пролонгированная лекарственная форма прамипексола в лечении болезни Паркинсона. Эффективная фармакотерапия. 2012;(4):14–8. [Obukhova AV, Artem’ev DV. The new prolonged dosage form of a pramipeksol in treatment of an illness of Parkinson. Effektivnaya farmakoterapiya. 2012;(4):14–8. (In Russ.)]; Hauser RA, Schapira AH, Rascol O. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson’s disease. Mov Disord. 2010 Nov 15;25(15):2542–9. DOI: http://dx.doi.org/10.1002/mds.23317.; Poewe W, Barone P, Hauser RA, et al. Pramipexole extended-release is effective in early Parkinson’s disease. Movt Disord. 2009;24(Suppl 1):S273.; Hauser RA, Schapira AH, Barone P, et al. Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson’s disease. Eur J Neurol. 2014 May;21(5):736–43. DOI: http://dx.doi.org/10.1111/ene.12375.; Poewe W, Rascol O, Barone P. Extendedrelease pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology. 2011 Aug 23;77(8):759–66. DOI: http://dx.doi.org/10.1212/WNL. 0b013e31822affb0.; Schapira A, Barone P, Hauser RA, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011 Aug 23;77(8):767–74. DOI: http://dx.doi.org/10.1212/WNL.0b013e31822affdb.; Hauser RA, Gordon MF, Mizuno Y, et al. Minimal clinically important difference in Parkinson’s disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis. 2014. DOI: http://dx.doi.org/10.1155/2014/467131.; Rascol O, Barone P, Hauser RA. Efficacy, safety, and tolerability of overnight switching from immediate – to once daily extended-release pramipexole in early Parkinson’s disease. Mov Disord. 2010 Oct 30;25(14):2326–32. DOI: http://dx.doi.org/10.1002/mds.23262.; Тумгоева АИ, Шиндряева НН, Левин ОС. Приверженность к терапии больных с болезнью Паркинсона. Уральский медицинский журнал. 2011;(10):58–62. [Tumgoeva AI, Shindryaeva NN, Levin OS. Patient compliance with Parkinson’s disease. Ural’skii meditsinskii zhurnal. 2011;(10):58–62. (In Russ.)]; Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001 Aug;23(8):1296–310. DOI: http://dx.doi.org/10.1016/S0149-2918(01)80109-0.; Grosset КА, Bone I, Grosset D. Suboptimal medication adherence in Parkinson’s disease. Mov Disord. 2005;20(11):1502–7. DOI: http://dx.doi.org/10.1002/mds.20602.; Schapira AH, Barone P, Hauser RA, et al. Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson’s disease. Eur J Neurol. 2013 Jan;20(1):50–6. DOI: http://dx.doi.org/10.1111/j.1468-1331.2012.03712.x.; Белоусов ДЮ, Афанасьева ЕВ, Ефремова ЕА. Фармакоэкономический анализ применения противопаркинсонических препаратов в режиме монотерапии на ранних стадиях болезни Паркинсона. Качественная клиническая практика. 2013;(1):27–43. [Belousov DYu, Afanas'eva EV, Efremova EA. The farmacoekocomical analysis of application the antiparkinsonic preparations in the monotherapy mode at early stages of an illness of Parkinson. Kachestvennaya klinicheskaya praktika. 2013;(1):27–43. (In Russ.)]
-
15Academic Journal
Authors: Обухова, Анастасия
Subject Terms: БОЛЕЗНЬ ПАРКИНСОНА, АГОНИСТЫ ДОФАМИНОВЫХ РЕЦЕПТОРОВ, PARKINSON ''S DISEASE
File Description: text/html
-
16Academic Journal
Authors: Алексей, Вячеславович, Сергей, Николаевич
Subject Terms: болезнь Паркинсона, агонисты дофаминовых рецепторов, Мирапекс ПД, постоянная дофаминергическая стимуляция
File Description: text/html
-
17Academic Journal
Authors: Богданов, Ринат, Борисова, Снежана, Котов, Сергей
File Description: text/html
-
18Academic Journal
Source: Нервные болезни.
Subject Terms: БОЛЕЗНЬ ПАРКИНСОНА,ПРОДОЛЖИТЕЛЬНАЯ ДОФАМИНЕРГИЧЕСКАЯ СТИМУЛЯЦИЯ,АГОНИСТЫ ДОФАМИНОВЫХ РЕЦЕПТОРОВ,МИРАПЕКС ПД
File Description: text/html
-
19Academic Journal
Source: Вестник Казахского Национального медицинского университета.
Subject Terms: паркинсонизм, холинолитические препараты, производные аминоадамантана, ДОФА-содержащие средства, ингибиторы моноаминоксидазы типа Б, ингибиторы катехол-О-метилтрансферазы и агонисты дофаминовых рецепторов, 3. Good health
File Description: text/html
-
20Academic Journal
Authors: Таряник, Катерина Анатоліївна, Литвиненко, Наталія Володимирівна, Таряник, Екатерина Анатольевна, Литвиненко, Наталья Владимировна, Taryanyk, K. A., Lytvynenko, N. V.
Subject Terms: агоністи дофамінових рецепторів, немоторні флуктуації, хвороба Паркінсона, амантадини, амантадины, немоторные флуктуации, болезнь Паркинсона, агонисты дофаминовых рецепторов, dopamine receptor agonists, non-motor fluctauations, Parkinson's disease, amantadine
File Description: application/pdf
Relation: Таряник К. А. Корекція немоторних флуктуацій у хворих із хворобою паркінсона на фоні лікування препаратами леводопи / К. А. Таряник, Н. В. Литвиненко // Актуальні проблеми сучасної медицини . – 2013. – Т. 13, вип. 3 (43). – С. 282–285.; https://repository.pdmu.edu.ua/handle/123456789/6313
Availability: https://repository.pdmu.edu.ua/handle/123456789/6313
